Complement 3 glomerulopathy (C3G) is diagnosed with a combination of a clinical evaluation, blood tests, urine tests, and a renal (kidney) biopsy. The only way to definitively diagnose C3G and its ...

Chinese scientists are testing whether cyanobacteria, the photosynthetic microorganisms that have shaped Earth’s soils for billions of years, can convert barren desert sand into ground capable of ...

The quest for immortality may seem the preserve of Greek myth or science fiction – or the Silicon Valley super-rich – but it seems to be affecting ordinary people, too. Longevity Fixation Syndrome is ...

Add Yahoo as a preferred source to see more of our stories on Google. USC Roski Eye Institute researchers are launching a phase 2b trial of a stem cell retinal implant designed to replace damaged ...

The start-up Function will send practically anyone to a lab for extensive medical testing, no physical required. Is that a good thing? By Kristen V. Brown As Kimberly Crisp approached middle age, ...

If it feels like everyone is getting the flu, you're not imagining it. This is shaping up to be another severe flu season. That's why it's important to take advantage of every tool we have to keep the ...

GYEONGJU, South Korea — President Donald Trump said Wednesday he had instructed the Defense Department to “immediately” start testing nuclear weapons "on an equal basis" with other nations. “Because ...

Novo Nordisk is paying $240 million for global rights to a Phase 3-ready drug from Omeros that could rival immune disorder medications currently available from companies such as AstraZeneca, Novartis, ...

Complement 3 glomerulopathy (C3G) is a rare kidney disease that affects your body’s innate immune system (complement system). Complement 3 glomerulopathy (C3G) is a kidney disease that’s caused by ...

Centauri plans the progression of lead candidate, an immunotherapy based broad-spectrum antimicrobial, to a first in human clinical study in early 2026 CARB-X’s additional funding brings their ...

The pre-erythrocytic malaria vaccine R21 vaccine adjuvanted with Matrix-M reported good efficacy (75%) in an ongoing phase 3 trial and was recommended World Health Organization for use in children ...